NexImmune
33 articles about NexImmune
-
NexImmune, Yale, and JDRF Enter into Research Partnership for Type 1 Diabetes
5/10/2022
NexImmune, Inc., Yale and JDRF have begun a two-year project to explore the use of NexImmune’s AIM nanoparticles in combination with an anti-CD3 mAb to tolerize, deplete or modulate diabetes antigen-specific T cells.
-
NexImmune Announces Appointment of Dr. Leena Gandhi to its Board of Directors
5/10/2022
NexImmune, Inc. (Nasdaq: NEXI), today announced the appointment of Leena Gandhi, M.D., Ph.D., Director for the Center of Therapeutic Innovation at Dana-Farber Cancer Institute, to its Board of Directors as a Non-Executive Director.
-
NexImmune Announces Preclinical Research Collaboration with Columbia University Irving Medical Center’s Herbert Irving Comprehensive Cancer Center
4/26/2022
NexImmune, Inc. today announced a preclinical research collaboration with Columbia University Irving Medical Center’s (CUIMC) Herbert Irving Comprehensive Cancer Center (HICCC).
-
NexImmune Promotes Mathias Oelke, Ph.D., To Chief Scientific Officer
4/14/2022
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Mathias Oelke, Ph.D., has been promoted to Chief Scientific Officer.
-
NexImmune and Zephyr AI Announce a Strategic Partnership in Oncology for Target Discovery and Validation
3/17/2022
NexImmune, Inc. and Zephyr AI announced a strategic partnership focusing on the discovery and validation of novel targets for new T-cell-mediated therapies in oncology.
-
NexImmune Announces Melanoma Research Collaboration with NYU Langone’s Perlmutter Cancer Center
3/14/2022
NexImmune, Inc. today announced a research and evaluation collaboration with The Laura and Isaac Perlmutter Cancer Center, a National Cancer Institute designated Comprehensive Cancer Center and part of NYU Langone Health.
-
NexImmune to Present at the Barclays 2022 Global Healthcare Conference
3/10/2022
NexImmune, Inc. announced that Kristi Jones, Chief Executive Officer, will present at the Barclays 2022 Global Healthcare Conference on Thursday, March 17, 2022 at 8:30 a.m. Eastern Time.
-
NexImmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates
3/9/2022
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today reported its fourth quarter and full year financial results for the full year 2021.
-
NexImmune Appoints Kristi Jones as Chief Executive Officer and Member of the Board of Directors
2/17/2022
NexImmune, Inc. announced that Kristi Jones has been appointed as the Company’s Chief Executive Officer and a member of its Board of Directors.
-
NexImmune Announces Research Collaboration with Rutgers, The State University of New Jersey, Related to Neuroendocrine Tumor Targets
2/1/2022
NexImmune, Inc. today announced a collaboration with Rutgers, The State University of New Jersey.
-
Various pharmaceutical companies announced collaborations and licensing agreements from January 31 to February 1.
-
NexImmune to Participate in The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Panel on “Expanding the Possible with Next-Generation Cell Therapies”
1/18/2022
NexImmune, Inc. (Nasdaq: NEXI), today announced that Scott Carmer, Chief Executive Officer, will participate in the LLS TAP panel discussion entitled “Expanding the Possible with Next Generation Cell Therapies” on Friday, January 21, 2022 at 12:00 p.m. Eastern Time.
-
NexImmune Announces Formation of Autoimmune and Infectious Diseases Scientific Advisory Board
1/5/2022
NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced the formation of its Autoimmune and Infectious Disease Scientific Advisory Board (AI & ID SAB).